ConvaTec Group PLC Non-Executive Director appointment (3330E)
27 Febbraio 2020 - 12:00PM
UK Regulatory
TIDMCTEC
RNS Number : 3330E
ConvaTec Group PLC
27 February 2020
ConvaTec Group PLC
Non-Executive Director appointment
Reading, United Kingdom (27 February 2020)
ConvaTec Group Plc ("ConvaTec" or "the Company") announces the
appointment of Brian May as a Non-Executive Director of the Company
and member of the Audit and Risk Committee and Remuneration
Committee with effect from 2 March 2020.
Brian has extensive financial and international business
experience. He has overseen significant strategic growth
initiatives resulting in both organic and inorganic growth and
sustained shareholder returns over the long term through strong
capital allocation.
Brian was formerly Chief Financial Officer of Bunzl plc from
2006 to 2019 and, prior to that, he held a number of senior
management finance roles with Bunzl, including divisional Finance
Director, Group Treasurer and Head of Internal Audit. He qualified
as a Chartered Accountant with KPMG in 1988.
John McAdam, Chairman of ConvaTec, commented:
"I am delighted that Brian is joining our Board. He has
considerable financial experience and expertise. Furthermore, he
has a detailed understanding of the challenges and opportunities
that arise as a result of transformational change. As we focus on
pivoting to sustainable and profitable growth, I am confident that
he will make a valuable contribution to the Board."
Brian is currently a Non-Executive Director of United Utilities
Group plc and Chair of its Audit and Treasury Committees
.
No other information requires disclosure in accordance with
Listing Rule 9.6.13.
This announcement is made in accordance with Listing Rule
9.6.11R(1).
Enquiries:
Analysts and Investors
Mark Reynolds, Director Investor Relations +44 (0)7551 036
625
investorrelations@convatec.com
Media
Buchanan: Charles Ryland/Chris Lane/Vicky Hayns +44 (0)207 466
5000
About ConvaTec
ConvaTec is a global medical products and technologies company
focused on therapies for the management of chronic conditions. The
Company is listed on the London Stock Exchange (stock symbol: CTEC)
and has established market positions in advanced wound care, ostomy
care, continence and critical care, and infusion care. ConvaTec's
products provide a range of clinical and economic benefits,
including infection prevention, protection of at-risk skin,
improved patient outcomes and reduced total cost of care.
www.convatecgroup.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAKKOBBFBKKDBB
(END) Dow Jones Newswires
February 27, 2020 06:00 ET (11:00 GMT)
Grafico Azioni Convatec (LSE:CTEC)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Convatec (LSE:CTEC)
Storico
Da Apr 2023 a Apr 2024